CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress

Core Insights - CytoSorbents Corporation will present at the 1st Annual AAPI World Health Congress, highlighting its role in blood purification for critically ill patients [1][2] - The company aims to increase awareness of its technologies among healthcare professionals and discuss the impact of artificial intelligence in critical care [2] - CytoSorbents' lead product, CytoSorb®, is approved in the EU and used in 75 countries, addressing cytokine storms in critical illnesses [3] Company Overview - CytoSorbents Corporation specializes in blood purification technologies for life-threatening conditions in intensive care and cardiac surgery [3] - The company has utilized over 237,000 CytoSorb devices as of March 31, 2024, and has received FDA Emergency Use Authorization for COVID-19 patients [3] - The DrugSorb™-ATR system has received two FDA Breakthrough Device Designations for antithrombotic removal during cardiothoracic procedures [4] Technology and Funding - The purification technologies are based on biocompatible polymer beads that remove toxic substances from blood [5] - CytoSorbents has secured approximately $50 million in funding from various U.S. government agencies, including DARPA and NIH [5] - The company holds numerous patents and has multiple products under development, including ECOS-300CY® and DrugSorb™ [5]